Overview

Trial to Evaluate Safety and Efficacy of Treatment of Physician Choice (TPC) Following First-Line Treatment of Lenvatinib in Subjects With Unresectable Hepatocellular Carcinoma (uHCC)

Status:
Terminated

Trial end date:
2019-01-07

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to assess the safety and tolerability of subsequent systemic treatment of physician's choice (TPC) following the first-line lenvatinib treatment in unresectable hepatocellular carcinoma (uHCC) participants.

Phase:

Phase 2

Details

Lead Sponsor:

Eisai Inc.

Treatments:

Lenvatinib